MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Oncology

Drive outcomes in oncology

Dysregulated metabolism is not only essential for the growth and proliferation of individual cancer cells; indeed, the physiology of the patient is as much a part of the equation as the tumor. Metabolomics can both identify cancer-specific drug targets and assess the patient’s phenotype more broadly, addressing key questions like who will respond to the therapy? How can we expand the pool of responders? How can we predict adverse events? Overall, metabolomics informs decision-making and positions development programs for success by providing a functional readout of the molecular phenotype.

TALK WITH AN EXPERT
See More Solutions
Target biology

Drug development in oncology often suffers from “Achilles heel” traits such as an absence of human genetic data linking the target to the disease, lack of access to a well-validated animal model of the disease or poor understanding of the target’s role in the underlying disease pathophysiology. Metabolomics has the capacity to arm your program for success by illuminating the right target through profound mechanistic understanding of the disease state.

Lead selection and optimization

It’s not always easy to predict toxicity from preclinical data or to demonstrate clear drug exposure and pharmacological activity on the target organ, but metabolomics can help ensure the right exposure and right safety profile by providing early biomarkers of both on- and off-target activity and toxicity.

Clinical success

A lack of efficacy biomarkers and an inability to stratify patients are among the leading causes of project failure. Metabolomics delivers the transformational key to identify the right patients & biomarkers as well as the right commercial potential.

Delve deeper into role of metabolites in immuno-oncology

The critical influence of the gut microbiome on the efficacy of immuno-oncology drugs is now well-established. How do microbes in the gut drive patient response in distal organs? Metabolomics provides a key piece of the puzzle by profiling the chemical signals that mediate the microbial modulation of host immunity. What’s more, the importance of metabolic reprogramming in T cell activation makes metabolomics a crucial tool in the development of robust and reproducible manufacturing processes for CAR-T and other cell-based therapies.

Reference: Based on AstraZeneca’s five-dimensional framework Cook, D, et al. Nat Rev Drug Discov 13, 419–431 (2014).

Study Design

Data Interpretation

Our Platform

Learn More

Related Resources

See All Resources
Methyl Donor Deficiency Blocks Colorectal Cancer Development by Affecting Key Metabolic Pathways

Methyl Donor Deficiency Blocks Colorectal Cancer Development by Affecting Key Metabolic Pathways

Prospective serum metabolomic profiling of lethal prostate cancer

Prospective serum metabolomic profiling of lethal prostate cancer

Overcoming Challenges in Microbiome Research: A Panel Discussion

Overcoming Challenges in Microbiome Research: A Panel Discussion

Load more

Enlighten your research,
accelerate your discovery.

Demo Our Data

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

    Get a Project Quote
    Send a Message
    Corporate Headquarters

    617 Davis Drive, Suite 100
    Morrisville, NC 27560

    Mailing Address:
    P.O. Box 110407
    Research Triangle Park, NC  27709

    +1 (919) 572-1711
    +1 (919) 572-1721
    International Headquarters

    Metabolon GmbH

    Zeppelinstraße 3
    85399 Hallbergmoos
    Germany

    +49 89 99017752

    Metabolomics

    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Insights & Discoveries

    Solutions

    • Products & Services
    • By Research & Development Phase
    • By Therapeutic Area
    • By Sector

    Insights

    • Our Latest Insights
    • Blog
    • News & Events
    • Publications

    Resources

    • Resource Library
    • Client Stories
    • COVID-19

    Company

    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
    Metabolon - Logo - Enlightening Life

    Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

    © 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

    in